A5008222365- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- DNA Repair Mechanisms
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Genetic Neurodegenerative Diseases
- Ubiquitin and proteasome pathways
- Statistical Methods in Clinical Trials
- Colorectal and Anal Carcinomas
- Ethics in Clinical Research
- Pericarditis and Cardiac Tamponade
- Metastasis and carcinoma case studies
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Algal biology and biofuel production
- Seaweed-derived Bioactive Compounds
- Marine and coastal plant biology
- Power System Optimization and Stability
- Power Systems Fault Detection
- Chemokine receptors and signaling
The University of Texas MD Anderson Cancer Center
2017-2025
Vietnam Academy of Science and Technology
2021
University of Da Nang
2020
National Yang Ming Chiao Tung University
2019
Academia Sinica
2019
Advanced Cancer Therapeutics
2018
Hiroshima University
2009
Abstract Background: As not all patients respond to immunotherapy, it is important identify who are likely benefit from treatment. Several factors such as hypoalbuminemia, elevated neutrophil counts, and increased LDH have been associated with poor response immunotherapy reduced survival outcomes. Similarly, liver metastases immune checkpoint inhibitors in melanoma non-small cell lung cancer. However, its impact across solid tumors the effect of location, number, size on treatment outcomes...
Abstract The concurrent use of medications can either compromise or enhance treatment (Tx) outcomes in patients with solid tumors (pts) receiving immunotherapy compounds (IO) including monoclonal antibodies (Abs), fusion proteins (FP), immune modulators (IM), oncolytic viruses (OV) and vaccines (VAC). To assess the impact on Tx outcomes, we conducted a retrospective analysis pts enrolled early IO clinical trials at Department Investigational Cancer Therapeutics (ICT) MD Anderson Center...
Mutations in the ATM gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement loss function (LOF) as a predictive biomarker response is urgently needed.
Pseudoprogression has been observed in patients with various tumor types treated immunotherapy. However, the frequency of pseudoprogression is unknown gastrointestinal malignancies. Metastatic colorectal cancer (mCRC) and advanced pancreatic ductal adenocarcinoma (PDAC) who progressed on treatment immunotherapy beyond RECIST version 1.1 criteria were analyzed. Degree progression, markers, time to overall survival, Eastern Cooperative Oncology Group Performance Status (ECOG PS), costs...
Vibriosis in farmed animals is a serious threat to aquaculture worldwide. Using probiotics and anti-Vibrio antimicrobial substances systems can be means of preventing Vibrio infections. Therefore, we aimed characterize compare 16 potential (Vi+) isolated from marine sponges fish intestines collected the Vietnam Sea, as well an bacteriocin fully explore their application potentials. 16S rRNA sequencing confirmed all Vi+ Bacillus species with different strain variants across two sample types....
e18594 Background: Ethically and scientifically clinical trials must be equally accessible. Unfortunately, racial ethnic minorities, socioeconomically disadvantaged, elderly rural populations continue to underrepresented in all phases of cancer due multiple interrelated economic, cultural, social medical barriers. Per U.S. 2010 census data about 57 million people (18-19% the population) 84% land mass qualify as rural. Examining affect geographic distance from trial sites residency on patient...
Background Decreased tumor content (TC) in resection specimens after neoadjuvant therapy is used to predict prognosis. We investigated whether TC assessed biopsy or the shift from baseline on-treatment can be accordingly response patients with rare tumors who were treated pembrolizumab. Methods A total of 57 (represented by 173 and 179 biopsies) participating an ongoing phase II clinical trial pembrolizumab evaluated. was estimated on H&E-stained slides dichotomized into low high...
Abstract Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records 43 platinum-refractory cancer who participated one or more phase I trials various investigational Patients' tumors circulating tumor DNA were by next-generation sequencing. The median progression-free survival was 4.2 months, the overall 9.6 response rate 17.5%. TP53, ERBB2, PI3KCA, FGFR3, ARID1A alterations detected 66%, 29%,...
ABSTRACT Introduction For maximum utility of molecular characterization by next-generation sequencing (NGS) and better understanding tumor microenvironment with immune correlates analysis, biopsy specimens must yield adequate tissue, sequential should sample a consistent site. We developed web-based lesion selection tool (LST) that enables management tracking the specimen collections. Methods Of 145 patients, LST was used for 88 patients; other 57 served as controls. evaluated consistency...
<div>AbstractPurpose:<p>Mutations in the <i>ATM</i> gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement ATM loss function (LOF) as a predictive biomarker response is urgently needed.</p>Experimental Design:<p>We present first disclosure and preclinical development novel, selective ATR inhibitor, ART0380, test its antitumor activity cancer models. To refine LOF biomarker,...
<div>AbstractPurpose:<p>Mutations in the <i>ATM</i> gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement ATM loss function (LOF) as a predictive biomarker response is urgently needed.</p>Experimental Design:<p>We present first disclosure and preclinical development novel, selective ATR inhibitor, ART0380, test its antitumor activity cancer models. To refine LOF biomarker,...
<p>supplementary figures</p>
<p>supplementary figures</p>
2544 Background: Anti-tumor response and toxicity outcomes with adoptive cell therapy (ACT) have been heterogeneous in solid tumors, it is still unclear how host factors such as obesity may contribute to efficacy immune-related safety events. Methods: We conducted a retrospective study including 95 consecutive advanced tumor patients who received ACT on protocol the Department of Investigational Cancer Therapeutics between August 2017 June 2023. analyzed baseline clinical characteristics,...
<h3>Background</h3> Adoptive cell therapy (ACT) is a newly emerging treatment modality for solid tumors with heterogenous outcomes and limited biomarkers to guide patient selection. The relationship between tumor burden ACT efficacy poorly understood. We sought investigate whether CT-based volumetric analysis helps predict after the aim of improving <h3>Methods</h3> This retrospective study included consecutive patients advanced who received on protocol in Department Investigational Cancer...
This cohort study investigates the association of obesity with adoptive cell therapy outcomes in patients solid tumors.
This research has introduced the intelligent ANFIS-Online controller of STATCOM for improving dynamic voltage on power network under a 3-phase short circuit fault. The is made using an artificial neural identifier. And based identifier, premise and consequent parameters ANFIS are adjusted timely. To demonstrate performance suggested controller, transient waves shown to describe effectiveness enhance response system It's that provided better than other controllers such as ANFIS-PSO ANFIS-GA...
BackgroundFor patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test the safety, toxicity and optimal dosing of agents. Herein, we analysed outcomes mRCC enrolled in phase assess utility prognostic scores.MethodsPatients all histologies were included if they received treatment a trial at MD Anderson Cancer Center (MDACC). Survival calculated using Cox...